Stat5 Signaling Specifies Basal versus Stress Erythropoietic Responses through Distinct Binary and Graded Dynamic Modalities

PLoS Biology

Volumn 10, Issue 8, 2012, Pages

  Porpiglia, Ermelinda ^a   Hidalgo, Daniel ^a   Koulnis, Miroslav ^a   Tzafriri, Abraham R ^b   Socolovsky, Merav ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CBSET Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; PHOSPHOTYROSINE; STAT5 PROTEIN; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL ERYTHROPOIESIS; BASOPHIL; CELL DIFFERENTIATION; CELL STIMULATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EMBRYO; ERYTHROBLAST; ERYTHROPOIESIS; FETUS; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE STRAIN; NEWBORN ANEMIA; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; STRESS ERYTHROPOIESIS;

ANEMIA; ANIMALS; ANIMALS, NEWBORN; ANTIGENS, CD; CELL DIFFERENTIATION; CELLS, CULTURED; ERYTHROBLASTS; ERYTHROPOIESIS; FETUS; FLOW CYTOMETRY; LIVER; MICE; MODELS, BIOLOGICAL; PHOSPHORYLATION; RECEPTORS, ERYTHROPOIETIN; RECEPTORS, TRANSFERRIN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; STRESS, PHYSIOLOGICAL; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; UP-REGULATION;

MUS;

EID: 84865768673     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001383     Document Type: Article

References (52)

1. D'Andrea AD, Lodish HF, Wong GG, (1989) Expression cloning of the murine erythropoietin receptor. Cell 57: 277-285.
2. Wu H, Liu X, Jaenisch R, Lodish HF, (1995) Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83: 59-67.
3. Zang H, Sato K, Nakajima H, McKay C, Ney PA, et al. (2001) The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis. Embo J 20: 3156-3166.
4. Koulnis M, Liu Y, Hallstrom K, Socolovsky M, (2011) Negative autoregulation by Fas stabilizes adult erythropoiesis and accelerates its stress response. PLoS One 6: e21192 doi:10.1371/journal.pone.0021192.
5. Koulnis M, Porpiglia E, Porpiglia PA, Liu Y, Hallstrom K, et al. (2012) Contrasting dynamic responses in vivo of the Bcl-xL and Bim erythropoietic survival pathways. Blood 119: 1228-1239.
6. Socolovsky M, Fallon AEJ, Wang S, Brugnara C, Lodish HF, (1999) Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in bcl-XL induction. Cell 98: 181-191.
7. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, et al. (2001) Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98: 3261-3273.
8. Constantinescu SN, Ghaffari S, Lodish HF, (1999) The Erythropoietin receptor: structure, activation and intracellular signal transduction. TEM 10: 18-23.
9. Bunn HF, (2007) New agents that stimulate erythropoiesis. Blood 109: 868-873.
10. Jelkmann W, (2007) Erythropoietin after a century of research: younger than ever. Eur J Haematol 78: 183-205.
11. Longmore GD, (2006) A unique role for Stat5 in recovery from acute anemia. J Clin Invest 116: 626-628.
12. Zhu BM, McLaughlin SK, Na R, Liu J, Cui Y, et al. (2008) Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression. Blood 112: 2071-2080.
13. Levy DE, Darnell JE Jr, (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662.
14. Schindler C, Levy DE, Decker T, (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282: 20059-20063.
15. Marshall CJ, (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185.
16. Das J, Ho M, Zikherman J, Govern C, Yang M, et al. (2009) Digital signaling and hysteresis characterize ras activation in lymphoid cells. Cell 136: 337-351.
17. Socolovsky M, Murrell M, Liu Y, Pop R, Porpiglia E, et al. (2007) Negative autoregulation by FAS mediates robust fetal erythropoiesis. PLoS Biol 5: e252 doi:10.1371/journal.pbio.0050252.
18. Pop R, Shearstone JR, Shen Q, Liu Y, Hallstrom K, et al. (2010) A key commitment step in erythropoiesis is synchronized with the cell cycle clock through mutual inhibition between PU.1 and S-phase progression. PLoS Biol 8 doi:10.1371/journal.pbio.1000484.
19. Shearstone JR, Pop R, Bock C, Boyle P, Meissner A, et al. (2011) Global DNA demethylation during mouse erythropoiesis in vivo. Science 334: 799-802.
20. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP, (2005) Causal protein-signaling networks derived from multiparameter single-cell data. Science 308: 523-529.
21. Liu Y, Pop R, Sadegh C, Brugnara C, Haase VH, et al. (2006) Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood 108: 123-133.
22. Koulnis M, Pop R, Porpiglia E, Shearstone JR, Hidalgo D, et al. (2011) Identification and analysis of mouse erythroid progenitors using the CD71/TER119 flow-cytometric assay. J Vis Exp.
23. Goldbeter A, Koshland DE Jr, (1981) An amplified sensitivity arising from covalent modification in biological systems. Proc Natl Acad Sci U S A 78: 6840-6844.
24. Huang CY, Ferrell JE Jr, (1996) Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 93: 10078-10083.
25. Ferrell JE Jr, (2009) Q&A: cooperativity. J Biol 8: 53.
26. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Koo JW, et al. (1991) The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol 11: 1980-1987.
27. Klingmuller U, Bergelson S, Hsiao JG, Lodish HF, (1996) Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci U S A 93: 8324-8328.
28. Lodish HF, Ghaffari S, Socolovsky M, Tong W, Zhang J (2009) Intracellular signaling by the erythropoietin receptor. In: Elliott SG, Foote M, Molineux G, editors. Erythropoietins, erythropoietic factors, and erythropoiesis: molecular, cellular, preclinical, and clinical biology. 2nd ed. Basel: Birkhäuser. pp. 155-174.
29. Croker BA, Kiu H, Nicholson SE, (2008) SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19: 414-422.
30. Murray PJ, (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178: 2623-2629.
31. Lehninger AL, Nelson DL, Cox MM (2005) Lehninger principles of biochemistry. New York, N.Y.; Basingstoke: W.H. Freeman.
32. Tzafriri AR, Edelman ER, (2007) Quasi-steady-state kinetics at enzyme and substrate concentrations in excess of the Michaelis-Menten constant. J Theor Biol 245: 737-748.
33. Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, et al. (2004) Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 24: 8037-8047.
34. Kerenyi MA, Grebien F, Gehart H, Schifrer M, Artaker M, et al. (2008) Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood 112: 3878-3888.
35. Dolznig H, Grebien F, Deiner EM, Stangl K, Kolbus A, et al. (2006) Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR. Oncogene 25: 2890-2900.
36. Menon MP, Karur V, Bogacheva O, Bogachev O, Cuetara B, et al. (2006) Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest 116: 683-694.
37. Goodnough LT, Nemeth E, Ganz T, (2010) Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116: 4754-4761.
38. Cazzola M, Mercuriali F, Brugnara C, (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood 89: 4248-4267.
39. Beguin Y, (2003) Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 329: 9-22.
40. Lin JX, Li P, Liu D, Jin HT, He J, et al. (2012) Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 36: 586-599.
41. Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K, et al. (2005) Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell 7: 87-99.
42. Biggar SR, Crabtree GR, (2001) Cell signaling can direct either binary or graded transcriptional responses. Embo J 20: 3167-3176.
43. Ferrell JE Jr, (2002) Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. Curr Opin Cell Biol 14: 140-148.
44. Ozbudak EM, Thattai M, Lim HN, Shraiman BI, Van Oudenaarden A, (2004) Multistability in the lactose utilization network of Escherichia coli. Nature 427: 737-740.
45. Ruf F, Park MJ, Hayot F, Lin G, Roysam B, et al. (2006) Mixed analog/digital gonadotrope biosynthetic response to gonadotropin-releasing hormone. J Biol Chem 281: 30967-30978.
46. Jelkmann W, (2009) Efficacy of recombinant erythropoietins: is there unity of international units? Nephrol Dial Transplant 24: 1366-1368.
47. Cain JA, Xiang Z, O'Neal J, Kreisel F, Colson A, et al. (2007) Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood 109: 3906-3914.
48. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, et al. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671.
49. Mamot C, Rochlitz C, (2006) Targeting the epidermal growth factor receptor (EGFR)-a new therapeutic option in oncology? Swiss Med Wkly 136: 4-12.
50. Pardanani A, Tefferi A, (2011) Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol 18: 105-110.
51. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S, (2011) Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10: 127-140.
52. Okimoto RA, Van Etten RA, (2011) Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol 18: 89-97.